Payment overview · 2025
General Payments
$1,749.38
22 reported records · 13 companies
Healthcare provider profile · identity verified
Pai-Hsiang Chen, D.O
Allopathic & Osteopathic Physicians|Family Medicine · ARCADIA, CA · NPI 1063405892
Verified facts
What the public records show
CMS Open Payments records show Pai-Hsiang Chen, D.O received $1,749.38 in general payments during 2025 across 22 reported records.
PFIZER INC. accounted for 9.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Paxlovid.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $164.60 | 9.4% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $157.31 | 9.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.59 | 8.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $140.00 | 8.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $140.00 | 8.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $135.25 | 7.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 7.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.2% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $124.99 | 7.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.98 | 7.1% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $121.83 | 7.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $121.83 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,749.38 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $164.60 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $140.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $140.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $135.25 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $123.68 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.32 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 750 | 227 |
| Amlodipine Besylate | Amlodipine Besylate | 510 | 153 |
| Azithromycin | Azithromycin | 363 | 215 |
| Losartan Potassium | Losartan Potassium | 337 | 99 |
| Alendronate Sodium | Alendronate Sodium | 315 | 95 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 300 | 85 |
| Metformin Hcl | Metformin Hcl | 285 | 86 |
| Zolpidem Tartrate | Zolpidem Tartrate | 266 | 55 |
| Omeprazole | Omeprazole | 172 | 57 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 150 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 144 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 31 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 103 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 33 |
| Sildenafil Citrate | Sildenafil Citrate | 91 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 65 |
| Allopurinol | Allopurinol | 85 | 25 |
| Glipizide | Glipizide | 85 | 20 |
| Simvastatin | Simvastatin | 80 | 24 |
| Meloxicam | Meloxicam | 76 | 37 |
| Vascepa | Icosapent Ethyl | 70 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 19 |
| Jardiance | Empagliflozin | 67 | suppressed |
| Lisinopril | Lisinopril | 65 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 48 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 13 |
| Carvedilol | Carvedilol | 57 | 18 |
| Atenolol | Atenolol | 55 | 17 |
| Glimepiride | Glimepiride | 55 | 16 |
| Finasteride | Finasteride | 53 | 15 |
| Hydrocortisone | Hydrocortisone | 49 | 26 |
| Famotidine | Famotidine | 48 | 21 |
| Valsartan | Valsartan | 47 | 13 |
| Eliquis | Apixaban | 45 | 11 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 13 |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 39 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 20 |
| Creon | Lipase/Protease/Amylase | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 34 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Prolia | Denosumab | 28 | 20 |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 26 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Prednisone | Prednisone | 24 | 15 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 21 | suppressed |
| Entecavir | Entecavir | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 17 | 13 |
| Alprazolam | Alprazolam | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Gabapentin | Gabapentin | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 14 |
| Repaglinide | Repaglinide | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,749.38 · 22 records | PFIZER INC. | AREXVY, Cologuard Collection Kit, EVENITY, FARXIGA, Kerendia, Leqembi, NEFFY, OTEZLA, PAXLOVID, REPATHA, REXULTI, SHINGRIX, Symbravo, The Cologuard Plus Collection Kit, VOQUEZNA, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error